Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBOVAC2: Ad26.ZEBOV and MVA-BN-Filo Prime-Boost in Africa
NCT02564523Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2015
- Primary completion
- Feb 2019
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of zabdeno, Mvabea in Ebola virus disease (EVD), sponsored by Janssen Pharmaceutical. Started Nov 2015; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02564523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564523.